C5 Capital Partners with Ukraine’s Brave1 Accelerator to Advance Ukraine’s Defense Innovation
4.10.2024 17:46:00 CEST | Business Wire | Press release
C5 Capital, a specialist venture capital firm based in Washington DC and London announces a strategic partnership with Brave1, Ukraine’s premier defense technology accelerator. This collaboration will support Ukraine’s innovative tech startups, accelerating the development and application of critical technologies for the defense of Ukraine against Russian aggression.
Brave1 leads Ukraine’s defense innovation ecosystem. Since its launch, the accelerator has evaluated more than 2,600 cutting-edge defense-focused innovations. This remarkable achievement has established Ukraine as emerging global leader in defense technology and innovation.
C5 Capital’s partnership will provide investment capital and strategic expertise needed to help Ukrainian founders grow and scale their defense startups, whose innovations are already being tested and deployed in battlefield conditions.
“C5 Capital’s strategic partnership with Brave1 is focused on empowering Ukraine’s courageous founders, who are building innovative companies in defense of Ukraine and all of us. Today there is nothing more important than fighting with allies,” said Andre Pienaar, the Founder of C5 Capital.
"Ukraine is emerging as a global leader in defense innovation and a powerhouse of research and development. Its defense tech startups showcase a relentless drive born from defending their homeland. We intend to bring our expertise developing and investing in innovative technologies for national defense to support victory for Ukraine,” said Rear Admiral Michael Hewitt, Co-Founder and CEO of IP3.
Ukraine: The New Hub of Defense Innovation
The conflict in Ukraine has sparked a wave of technological breakthroughs, especially in artificial intelligence (AI) and autonomous systems. Often referred to as the "algorithm war," AI-driven tools have played a pivotal role in processing vast amounts of battlefield data, enabling Ukraine to respond faster and more effectively.
Brave1 plays a crucial role in fast-tracking the development and deployment of such technologies. By connecting startups with essential resources, the accelerator transforms concepts into operational systems at an accelerated pace.
The Need for Private Investment
Brave1 issued $7.5 million in grants for startups and aims to scale funding in 2024. Over the first two years of the war, Ukrainian startups have attracted more than $20M of global investment.
“Private investment is essential for sustaining innovation in defense technology,” said Natalia Kushnerska, Brave1 Project Lead. “Our partnership with C5 is a crucial step toward building a resilient and innovative ecosystem. The technologies developed in Ukraine today will define the future of global defense.”
For more information on this strategic alliance, please visit the full article and interview published by National Security News: Ukraine Boosts Military Innovation to Confront Russian Hostilities Independently.
About C5 Capital:
C5 Capital (C5) is a specialist venture capital firm that invests in cybersecurity, space and energy security. C5's investment strategy is focused on building long-term relationships with resilient founders that share in our mission to enhance national security and build a secure digital future. C5 Capital is based in Washington, DC and London. For more information, visit: www.C5Capital.com.
About Brave1:
Brave1 is a cluster for the defense tech development in Ukraine, established by the Ministry of Digital Transformation, the Ministry of Defense, the General Staff of the Armed Forces of Ukraine, the National Security and Defense Council, the Ministry for Strategic Industries, and the Ministry of Economy. For more information, visit: https://brave1.gov.ua/en/
View source version on businesswire.com: https://www.businesswire.com/news/home/20241004928916/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom